- Previous Close
5.7200 - Open
5.6200 - Bid --
- Ask --
- Day's Range
4.7000 - 5.7200 - 52 Week Range
2.8900 - 14.1000 - Volume
27,534 - Avg. Volume
22,545 - Market Cap (intraday)
140.002M - Beta (5Y Monthly) 0.45
- PE Ratio (TTM)
-- - EPS (TTM)
-0.5500 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
19.10
Hyloris Pharmaceuticals SA engages in the research, development, and manufacture of pharmaceutical products to address unmet medical needs. The company offers Maxigesic IV, a combination of paracetamol and ibuprofen sodium dihydrate used for post-operative pain; Podofilox Gel, an antimycotic drug for the treatment of external genital and perianal warts caused by various types of the human papilloma virus; and Sotalol IV to treat atrial fibrillation. It also develops Aspirin IV and HY-074 IV to reduce the risk of morbidity and mortality associated with an emergency cardiac event, such as myocardial infarction or stroke; Milrinone ER for right heart failure due to left ventricular device; Dofetilide IV to treat atrial fibrillation; Metolazone IV for the treatment of salt and water retention, including edema accompanying congestive heart failure and renal diseases; and HY-075 IV to prevent and treat cardiovascular diseases. In addition, the company offers other value-added products comprising Tranexamic Acid Oral Rinse for preventing and treating excessive bleeding in patients on blood thinners undergoing dental procedures; Alenura to treat pain associated with interstitial cystitis/bladder pain syndrome; Miconazole/Domiphen Bromide cream for recurrent vulvovaginal candidiasis; PTX-252 to treat acute myeloid leukemia; Atomoxetine oral Liquid for the treatment of attention deficit hyperactivity disorder; HY-083 to treat idiopathic rhinitis; HY-088 for hypophosphatemia; HY-090 to treat burning mouth syndrome; and HY-091 for vulvar lichen sclerosis. The company was incorporated in 2012 and is headquartered in Liège, Belgium.
hyloris.comRecent News: HYL.BR
View MorePerformance Overview: HYL.BR
Trailing total returns as of 9/12/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: HYL.BR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: HYL.BR
View MoreValuation Measures
Market Cap
140.00M
Enterprise Value
111.35M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
67.08
Price/Book (mrq)
3.58
Enterprise Value/Revenue
53.35
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-18.27%
Return on Equity (ttm)
-33.08%
Revenue (ttm)
4.21M
Net Income Avi to Common (ttm)
-15.38M
Diluted EPS (ttm)
-0.5500
Balance Sheet and Cash Flow
Total Cash (mrq)
30.91M
Total Debt/Equity (mrq)
4.48%
Levered Free Cash Flow (ttm)
-7.44M